Method for detecting medicine adverse reaction with genome expression profiling

Abstract

The invention relates to a method for detecting medicine adverse reaction with a genome expression profiling, which comprises the following steps: inquiring and confirming known medicines that can trigger specifical adverse reaction, namely risk medicines; counting the frequency of the adverse reaction of the risk medicines; utilizing the risk medicines and target medicines to respectively process human or animal cell lines, and obtaining the whole genome expression profiling of the cell lines through a genome expression chip technical platform; and counting the similarity of the target medicines and the corresponding risk medicines on the genome expression profiling, and carrying out weighting calculation for the similarity of the expression profiling according to the relative frequency of the adverse reaction of the risk medicines so as to score and judge the risk of the target medicine triggering the adverse reaction. The detection method is suitable for all kinds of medicines, without limitation, is simple and easy to operate, can indirectly estimate the risk of the target medicine triggering the adverse reaction without at the cost of practical personal injury, and has excellent application prospect for clinical medicine risk assessment.

Description

technical field [0001] The invention belongs to the field of clinical drug safety evaluation and detection, in particular to a method for detecting adverse drug reactions through genome expression profiles. Background technique [0002] Due to serious adverse drug reactions caused by drug users, many drugs will be abandoned in the early stages of clinical development, or subject to sales bans or safety warnings by regulatory authorities after marketing. At present, the prevention and monitoring of adverse drug reactions mainly include two methods. On the one hand, in the early stage of drug development, the safety risks of drugs can be predicted in advance through means such as compound structure-activity relationship or animal toxicology experiments, and high-risk drug candidates can be abandoned early. However, practice has proved that risk screening in the early stage of research and development cannot completely avoid the occurrence of adverse reactions, and a considera...

AI Technical Summary

Problems solved by technology

However, practice has proved that risk screening in the early stage of research and development cannot completely avoid the occurrence of adverse reactions, and a considerable number of risky drugs have entered large-scale clinical trials and even entered the marketing stage

On the other hand, in large-scale clinical trials or after the drug is marketed, the safety warning and intervention of specific drugs can be realized by monitoring the frequency of specific adverse reactions, but such retrospective monitoring methods often have obvious hysteresis. Before safety problems are discovered, a considerable degree of personal injury and economic loss are often unavoidable

Images